Christoph B. Olivier: CYP2C19 Genotype, Platelet Reactivity and Risk Stratification in AF Patients Undergoing PCI
Christoph B. Olivier, Head of the Clinical Trials Unit, UHZ Freiburg, shared on LinkedIn about a recent article he and his colleagues co-authored, published in ASCPT:
”We are excited to share our latest publication: CYP2C19 Polymorphism and Platelet Aggregation-Associated Risks in Atrial Fibrillation Patients Undergoing PCI
Patients with atrial fibrillation undergoing PCI are among the highest-risk groups in interventional cardiology, facing competing ischemic and bleeding risks under complex antithrombotic therapy.
We assessed whether CYP2C19 genotype and platelet reactivity testing improve risk stratification in this vulnerable population.
Key findings:
- Poor/intermediate CYP2C19 metabolizer status might indicate lower bleeding risk
- High platelet reactivity identified patients at increased ischemic risk
- Low platelet reactivity was strongly associated with major bleeding
While larger studies are needed, such approaches may help improve risk stratification and guide individualized antithrombotic therapy.
A huge thank you to all the authors and colleagues for their incredible work on this project: Diona Gjermeni, Sofia Szabó, Viktoria Anfang, Hannah Vetter, Carina Juelch, Svenja Rademacher, Tian Li, Stefan Leggewie, Dr. David Hesselbarth, Daniel Duerschmied, Dietmar Trenk, Dirk Westermann.”
Title: CYP2C19 Polymorphism and Platelet Aggregation-Associated Risks in Atrial Fibrillation Patients Undergoing PCI
Authors: Diona Gjermeni, Sofia Szabó, Viktoria Anfang, Hannah Vetter, Carina Juelch, Svenja Rademacher, Tian Li, Stefan Leggewie, David Hesselbarth, Daniel Duerschmied, Dietmar Trenk, Dirk Westermann, Christoph B. Olivier
Stay updated on all scientific advances with Hemostasis Today.
-
Aug 21, 2026, 11:02Severe ITP, Critical Bleeding, and the Challenge of Platelet Testing – RPTH Journal
-
Aug 21, 2026, 10:46Arwa Z. Al-Riyami: Looking Ahead to ISBT Muscat 2029
-
Aug 21, 2026, 10:42Janine Mothershed: What Is Romiplostim and How Does It Work in Immune Thrombocytopenia?
-
Aug 21, 2026, 10:33Omar Alkharabsheh: Excited to Build the Future of Hematologic Malignancy Care in Central Florida
-
Aug 21, 2026, 10:23Salvador Payán Pernía: Tailoring Therapy in Sickle Cell Disease – Mitapivat and the Path Toward Personalized Combination Care
-
Aug 21, 2026, 10:10Pete Stibbs: The Evolving Landscape of VTE Management
-
Aug 21, 2026, 09:58Nishant K Mishra։ When Epilepsy Meets Anticoagulation
-
Aug 21, 2026, 09:07Sujal Lohana: Building a Better Blood Donor–Seeker App
-
Aug 21, 2026, 08:55Robert Sidonio: Connecting Experts in Bleeding and Clotting Disorders